• the best strategies for the ageing spine
• imitating nature – innovative biomaterials and implants
• the most important bone grafts and biologics
• chances and risks associated with biologic therapies
• recent cell therapies for intervertebral disc regeneration
• personalized medicine – integrating patients biology into surgical planning
Dear colleagues and friends,
On behalf of the Board of the European Network for Regenerative Medicine, I am pleased to invite you to Berlin from April 8–11, 2015 to participate in our 5th International Congress on Biotechnologies for Spinal Surgery (BioSpine).
Over the 12 years that have elapsed since launching BioSpine in 2002, the focus on high end development of many new nano- and biotechnology products within the scope of spinal surgery has been extraordinary. Currently, almost all industrial partners have included „ BioSpine-Products“ in their portfolio. Nevertheless there are still noticeable differences regarding both the quality of academic support and the efficiency of introducing new products to the market. In particular, the clinical knowledge contribution from the medical point of view remains limited and will require ongoing support from the academics as well as from industry to sustain progress and improve therapeutic options.
BioSpine has set itself the task to act as a catalyst between these two groups; to support doctors’ curiosity and demand for new information, and at the same time to request that industrial partners elucidate product information with appropriate scientific scrutiny. Biomaterials in spine surgery have moved far beyond the role of “bone void fillers” like it used to be 10 years ago. That evolution has resulted in products that are now characterized as growth factors, cell products and combined products; each of which might follow various regulations to meet clinical use approval. BioSpine was initiated to give insights into technology development, has the aim to impart understanding and acceptance, but also wants to sharpen a critical view.
Much the same as 12 years ago, BioSpine depends upon the financial and scientific support of industrial partners to present products, to facilitate their comprehension, to identify potentials for development, to unite scientists and physicians, and to interpret in turn into their respective languages. BioSpine not only shows openness to the end-consumer, the surgeon, but further recognizes the importance of incorporating the scientist into a common dialogue in order to provide parallel direction for future industrial research.
Science subsists from the lively exchange of information. Join us for this fantastic opportunity, for fruitful conversations, for vigorous discussions and the mutual exchange of knowledge.
I cordially invite you all to attend the BioSpine congress and look forward to meeting you in Berlin in April 2015.
On behalf of the Organizing Committee and Advisory Board,
Hans Jörg Meisel, MD, PhD